Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | CES1 | P23141 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31210112 | 0.85 | CA12 (0.62) | CES2CES1CA1CA2LMNA | |
| SCHEMBL26690845 | 0.85 | CA12 (0.62) | CES2CES1CA1CA2LMNA | |
| SCHEMBL2183846 | 0.84 | CES2 (0.48) | CES2CES1CA1CA2LMNA | |
| SCHEMBL29738515 | 0.84 | TTR (0.56) | CES2CES1CA1CA2LMNA | |
| SCHEMBL2431319 | 0.84 | TTR (0.56) | CES2CES1CA1CA2LMNA | |
| SCHEMBL23815308 | 0.84 | TPMT (0.58) | CES2CES1CA1CA2LMNA | |
| SCHEMBL30753326 | 0.84 | TTR (0.56) | CES2CES1CA1CA2LMNA | |
| SCHEMBL1724284 | 0.84 | TTR (0.56) | CES2CES1CA1CA2LMNA | |
| SCHEMBL14213195 | 0.83 | TTR (0.55) | CES2CES1CA1CA2LMNA | |
| SCHEMBL542833 | 0.81 | LMNA (0.50) | CES2CES1CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754797-B | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118754797-A | Synthesis method of 3,4, 5-trifluoro-bromobenzene | 台州鸿都生物科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-117832755-A | Functional diaphragm for lithium-sulfur battery and preparation method thereof | 成都职业技术学院 | 2024-04-05 | — | — | CN | claimed |
| CN-117596997-A | Semitransparent polymer solar cell and preparation method thereof | 四川大学 | 2024-02-23 | — | — | CN | claimed |
| CN-115181054-A | Synthetic method of 3-benzyl indole compound | 合肥工业大学 | 2022-10-14 | — | — | CN | claimed |
| CN-114409887-A | Fluorinated terminal group amphiphilic polymer, and preparation method and application thereof | 浙江大学杭州国际科创中心 | 2022-04-29 | — | — | CN | claimed |
| CN-113956877-A | Preparation of organic fluorine-containing carbon quantum dot with near-infrared excitation/emission property | 重庆医科大学 | 2022-01-21 | — | — | CN | claimed |
| CN-112094586-B | High-wear-resistance hydrophobic coating and preparation method thereof | 丹阳市精通眼镜技术创新服务中心有限公司 | 2021-11-09 | — | — | CN | claimed |
| CN-112094586-A | High-wear-resistance hydrophobic coating and preparation method thereof | 丹阳市精通眼镜技术创新服务中心有限公司 | 2020-12-18 | — | — | CN | claimed |
| CN-107681052-B | Main group metal complexes as p-dopants for organic electronic matrix materials | 西门子公司 | 2020-03-24 | — | — | CN | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1511713-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | Canbas Co. Ltd. (JP) | 2005-03-09 | — | — | EP | claimed |
| US-20040198727-A1 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CANBAS CO., LTD. (JP) | 2004-10-07 | — | — | US | claimed |
| US-20040094297-A1 | Method for determining the extent of recovery of materials injected into oil wells or subsurface formations during oil and gas exploration and production | CORE LABORATORIES LP | 2004-05-20 | — | — | US | claimed |
| WO-2003104181-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO. LTD. (JP) | 2003-12-18 | — | — | WO | claimed |
| US-6659175-B2 | Mixing water, buffers, oxidizers, gels, gelation inhibitors, stabilizer and curing agents with tracers, then pumping the mixtures into bores, withdrawing fluids and measuring concentration of labels; well completion efficiency | CORE LABORATORIES, INC. | 2003-12-09 | — | — | US | claimed |
| US-20030006036-A1 | Mixing water, buffers, oxidizers, gels, gelation inhibitors, stabilizer and curing agents with tracers, then pumping the mixtures into bores, withdrawing fluids and measuring concentration of labels; well completion efficiency | CORE LABORATORIES GLOBAL N.V. (NL) | 2003-01-09 | — | — | US | claimed |
| WO-2002095189-A1 | METHOD OF DETERMINING THE EXTENT OF RECOVERY OF MATERIALS INJECTED INTO OIL WELLS | CORE LABORATORIES L.P. (US) | 2002-11-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198727-A1 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CDC25C, CHEK1, DDB1 | CES2 4525/4885CES1 3681/4885CA1 3472/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | CES2 1598/4885CES1 3489/4885CA1 102/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | CES2 2351/4885CES1 3786/4885CA1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.